7
Participants
Start Date
July 31, 2007
Primary Completion Date
January 31, 2009
Study Completion Date
December 31, 2009
Ranibizumab
0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
Proctor Foundation, UCSF, San Francisco
Collaborators (1)
Genentech, Inc.
INDUSTRY
University of California, San Francisco
OTHER